Shandong Buchang Pharmaceuticals Co., Ltd. (SHA:603858)
China · Delayed Price · Currency is CNY 15.10
-0.02 (-0.13%)
Nov 6, 2026, 3:00 PM CST
SHA:603858 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 15,672 | 16,493 | 16,838 | 18,814 | 23,238 | 23,326 | |
Market Cap Growth | -13.70% | -2.05% | -10.50% | -19.04% | -0.38% | -8.58% |
Enterprise Value | 16,385 | 18,263 | 19,100 | 21,044 | 23,744 | 25,505 |
Last Close Price | 15.10 | 14.98 | 14.82 | 15.82 | 18.60 | 18.31 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 56.11 | 45.72 | - | 58.98 | - | 18.09 |
Forward PE | - | 25.13 | 25.13 | 25.13 | 25.13 | 25.13 |
PS Ratio | 1.37 | 1.39 | 1.53 | 1.42 | 1.55 | 1.48 |
PB Ratio | 1.62 | 1.75 | 1.72 | 1.65 | 1.89 | 1.61 |
P/TBV Ratio | 1.71 | 1.88 | 1.92 | 2.05 | 2.52 | 2.87 |
P/FCF Ratio | 23.52 | 15.95 | 22.66 | - | 10.50 | 26.30 |
P/OCF Ratio | 18.17 | 14.25 | 17.91 | - | 8.43 | 17.67 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.43 | 1.54 | 1.74 | 1.59 | 1.59 | 1.62 |
EV/EBITDA Ratio | 11.01 | 11.29 | 14.88 | 13.06 | 10.53 | 11.42 |
EV/EBIT Ratio | 14.21 | 15.55 | 28.06 | 20.32 | 13.37 | 14.65 |
EV/FCF Ratio | 24.59 | 17.66 | 25.71 | - | 10.73 | 28.76 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.29 | 0.40 | 0.38 | 0.29 | 0.27 | 0.25 |
Debt / EBITDA Ratio | 1.87 | 2.31 | 2.86 | 2.02 | 1.45 | 1.57 |
Debt / FCF Ratio | 4.18 | 3.64 | 5.00 | - | 1.49 | 3.99 |
Net Debt / Equity Ratio | 0.14 | 0.27 | 0.25 | 0.20 | 0.03 | 0.13 |
Net Debt / EBITDA Ratio | 0.94 | 1.55 | 1.94 | 1.39 | 0.19 | 0.82 |
Net Debt / FCF Ratio | 2.07 | 2.43 | 3.36 | -3.10 | 0.19 | 2.06 |
Asset Turnover | 0.59 | 0.62 | 0.55 | 0.62 | 0.65 | 0.67 |
Inventory Turnover | 1.03 | 1.03 | 0.95 | 0.99 | 1.12 | 1.25 |
Quick Ratio | 0.46 | 0.41 | 0.37 | 0.45 | 0.71 | 0.57 |
Current Ratio | 1.27 | 1.10 | 1.06 | 1.21 | 1.29 | 1.17 |
Return on Equity (ROE) | 1.27% | 2.00% | -6.63% | 1.28% | -11.91% | 8.74% |
Return on Assets (ROA) | 3.73% | 3.81% | 2.12% | 3.02% | 4.83% | 4.64% |
Return on Invested Capital (ROIC) | 2.75% | 3.49% | 5.25% | 3.03% | 12.26% | 7.92% |
Return on Capital Employed (ROCE) | 9.00% | 9.70% | 5.60% | 7.40% | 11.80% | 10.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.78% | 2.19% | -3.29% | 1.70% | -6.58% | 5.53% |
FCF Yield | 4.25% | 6.27% | 4.41% | -3.86% | 9.52% | 3.80% |
Dividend Yield | 3.77% | 3.65% | - | 0.74% | 4.57% | 1.71% |
Payout Ratio | 117.88% | 147.10% | - | 374.41% | - | 57.88% |
Buyback Yield / Dilution | 1.17% | 2.55% | 2.01% | 0.00% | 0.01% | -0.01% |
Total Shareholder Return | 4.95% | 6.19% | 2.01% | 0.74% | 4.57% | 1.70% |